FDA Updates Medical Device Data Integrity Notification: Verify Third-Party Test Data Before Submission

FDA Updates Medical Device Data Integrity Notification

Source institution: U.S. Food and Drug Administration (FDA)

Original date: June 25, 2026

Publication date: June 25, 2026, 09:00

Original link: https://www.fda.gov/medical-devices/industry-medical-devices/notifications-data-integrity-medical-devices

Full Core Content of the FDA Notification

The FDA page reminds medical device manufacturers and sponsors to carefully evaluate third-party testing laboratories and to independently verify test data before submitting information to FDA. Data integrity issues may affect the credibility of marketing applications and may lead to requests for additional information, review delays, or regulatory action.

Test reports, performance data, clinical data, software validation data, and quality management system records in medical device registration submissions must be traceable, truthful, complete, and consistent. Companies cannot treat third-party reports as fully outsourced responsibilities; before submitting to regulatory authorities, they must still fulfill review and verification obligations.

For exporting companies, they should establish qualification assessment mechanisms for suppliers and testing laboratories, retain raw data, sample information, test conditions, report versions, and discrepancy explanations, and avoid data inconsistencies affecting FDA review.

AIMEILI Regulatory Interpretation

The AIMEILI Regulatory Affairs Department considers that updates related to GMP, supplier controls, and data integrity point to regulators' sustained focus on the credibility of evidence. Medical device registration is not simply a matter of submitting test reports, quality management system certificates, and technical documents; regulators will increasingly examine the manufacturing processes, outsourcing controls, supply chain changes, raw data, and record consistency behind those documents.

For companies, third-party testing, sterilization, software outsourcing, critical components, clinical data, performance validation, and quality management system records all need to be traceable. If supplier changes have not been assessed, test data lack raw records, or the manufacturing address, model specifications, process flows, and quality management system coverage in the registration dossier are inconsistent, problems may be exposed during review, system inspections, or postmarket investigations even if individual documents appear complete.

AIMEILI recommends that companies conduct a dossier credibility review before overseas registration: verify whether certificates, test reports, raw records, supplier agreements, change records, quality agreements, and technical documents are consistent. For companies preparing to enter markets such as Korea, the United States, the European Union, and Canada, quality management system evidence should be developed in parallel with the registration dossier, rather than explained temporarily after regulators raise questions.

Business Impact

The update may affect companies' registration pathway decisions, technical file preparation, labels and instructions for use, quality management system records, or postmarket maintenance arrangements. Companies should conduct company-specific assessments in light of target markets, product risk class, existing certificates, and sales plans, rather than simply reading regulatory news as ordinary information.

Recommended Compliance Actions

• Confirm whether the update affects existing registration pathways, certificate maintenance, or postmarket obligations.
• Check technical files, labels and instructions for use, quality management systems, and local responsible entity arrangements for target countries.
• Establish change impact assessments and regulatory update tracking records for marketed products.
• Where necessary, archive the official source text, regulatory interpretation, and action items to support future audits and project reviews.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Department

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supporting judgment.

Applicability boundary: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of target-country regulators, testing conclusions, or legal advice.